




Discuss changing the approach to diabetes management with individual and/or family if not already explored.
Ensure the Diabetes Specialist Team and GP (as appropriate) are involved and agree monitoring strategy



Important information

- Aim for glucose readings of 6 – 15mmol/L
- Avoid using a sliding insulin scale as these require frequent blood glucose monitoring
- Keep tests to a minimum. It may be necessary to perform some tests to ensure unpleasant symptoms do not occur due to low or high glucose
- It is difficult to identify symptoms due to “hypo” or hyperglycaemia in a dying person
- If symptoms are observed it could be due to abnormal blood glucose levels
- Test blood for glucose if the person is symptomatic
- Observe for hyperglycaemic symptoms such as thirst, clinical dehydration and increased urine output in previously insulin treated individuals where insulin has been discontinued
- Corticosteroids such as dexamethasone can contribute to hyperglycaemia and patients may require closer monitoring
- Continuous glucose monitoring (CGM) systems may be useful to avoid finger testing

* Examples of GLP1 Receptor Agonists

Diavic® (liraglutide),
Bydureon® (exenatide),
Trulicity® (dulaglutide),
Ozempic® & Rybelsus® (semaglutide)
Mounjaro® (Tirzepatide)
Note: combination products continue as long acting insulin only.
- Xultophy® (Liraglutide and insulin degludec)
- Suliqua® (Lixisenatide with insulin glargine)

**Table of Common Insulin Preparations

| Rapid acting | Short acting | Intermediate Isophane | Long acting (analogue) | Biphasic | Biphasic Isophane |
|--------------|--------------|-----------------------|------------------------|-----------------|-------------------|
| Apidra® | Actrapid® | Humulin I® | Abasaglar® | Humalog® Mix 25 | Humulin® M3 |
| Humalog® 100 | Humulin S® | | Lantus® | Humalog® Mix 50 | |
| Humalog® 200 | | | Levemir® | NovoMix® 30 | |
| NovoRapid® | | | Toujeo® | | |
| Fiasp® | | | Tresiba®100 | | |
| Lyumjev® | | | Tresiba®200 | | |

All insulins should be prescribed by **BRAND NAME**

Northern Ireland Formulary, available at <https://niformulary.hscni.net/>

Adapted from Trend Diabetes End of Life Guidance for Diabetes Care (2024) available at <https://trenddiabetes.online/> (registration required)

Developed by the NI Palliative Care in Partnership Clinical Engagement Group, in collaboration with Diabetes specialists

Guidance completed June 2025. Review date June 2028.

These recommendations are a GUIDE and should be used as such. They may differ from other recommendations but have been chosen to reflect expert opinion, best evidence, safety and local practice in NI. Responsibility for the use of these recommendations lies with the health care professional(s) managing each patient.